Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)

Status Recruiting

Clinical Trial Summary

A clopidogrel resistance rate of 40-50% has been found in the population over 70 years of age, whereas biological resistance, associated with an increased risk of cardiovascular events, is observed in about 20-30% of younger patients. One hypothesis is that the active metabolite is less available in resistant patients. Indeed, 85% of the absorbed clopidogrel undergoes inactivation by esterases. Then the remaining fraction undergoes two steps of metabolisation to the active thiol metabolite by CYP450, essentially the isoform 2C19. In older adults, increased esterase activity and/or decreased CYP450 2C19 activity may lead to a decreased concentration of the active metabolite. Multiple chronic conditions and polypharmacy encountered in older individuals are associated with basal platelet hyperactivity, and may also contribute to a poor response to clopidogrel. No data on the relationship between platelet response and circulating metabolite levels, or on the determinants of response to clopidogrel, are currently available in the geriatric population. Therefore, we propose to analyse the relationship between age and platelet and extra-platelet mechanisms potentially involved in the variability of response to clopidogrel.

Clinical Trial Description

This study is a prospective observational multi-centre study. The main objective is assessing the pharmacokinetics (PK) and pharmacodynamics (PD) correlation of clopidogrel action in older adults, i.e. correlation between clopidogrel active metabolite concentration (PK) and platelet response phenotype (PD). The primary outcome is the correlation between the concentration of active metabolite of clopidogrel (PK) over the percentage of maximum aggregation at 10 μM ADP (PD) as a function of age. Inclusion criteria are: age 50-100 years old, hospitalization in one of the 4 participating centres, treatment with clopidogrel 75 milligrammes per day, for at least 10 days. The statistical analysis is a multiple linear regression model with the introduction of an interaction term. The first variable of interest (explanatory) is the concentration of the metabolite. A linear regression model will be used to estimate the proportion of variance explained. The analyses will be conducted with SAS version 9.4 (SAS Institute Inc., Cary, N.C., USA). Results will be published in an international scientific review. ;

Study Design

Related Conditions & MeSH terms

Drug Resistance

Clinical Trial Details

NCT number	NCT04990596
Study type	Observational
Source	Rennes University Hospital
Contact	Joaquim PRUD'HOMM, MD
Phone	2 99 28 41 10
Email	joaquim.prud'homm@chu-rennes.fr
Status	Recruiting
Phase
Start date	July 12, 2021
Completion date	January 12, 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04516395` - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae	N/A
Terminated	`NCT00319150` - REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial	Phase 3
Completed	`NCT00563875` - Laboratory Aspirin Resistance in Diabetics and Non-Diabetics	N/A
Completed	`NCT00389129` - Danish Aspirin Resistance Trial - Pilot Study	N/A
Terminated	`NCT00193947` - An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy	Phase 4
Enrolling by invitation	`NCT06037564` - B-free Multistage Trial	Phase 4
Completed	`NCT04326868` - Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon	Phase 4
Completed	`NCT01039480` - Aspirin and Clopidogrel Resistance Study	N/A
Recruiting	`NCT05310370` - HRD and Resistance to PAPPi in EOC Patients
Active, not recruiting	`NCT00457236` - Effect of Clopidogrel Loading and Risk of PCI	N/A
Completed	`NCT02792816` - Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar	N/A
Completed	`NCT01386476` - (18F)FCWAY and the Blood-Brain Barrier
Recruiting	`NCT03401957` - The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment	N/A
Completed	`NCT04404582` - Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection
Completed	`NCT02401204` - Bacterial Transmission Dynamics Study
Completed	`NCT03114098` - Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs	N/A
Recruiting	`NCT03361267` - Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection	N/A
Completed	`NCT00302913` - Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition	N/A
Completed	`NCT04833231` - The Relationship Between Renal Functions and Multi Drug Resistant Organisms
Completed	`NCT00965042` - Effect of Ceftobiprole on Human Intestinal Microflora	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE) — CEPAGE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms